SBSusan H. Busch

Susan H. Busch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan H. Busch has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • First Experience With a New Active Bone Conduction Device in Pediatric Patients

    by Nils Prenzler, Marc Higgins, Thomas Lenarz, Hannes Maier, Mohammad Ghoncheh, Susan Busch

    Objective: The aim of this retrospective analysis was to evaluate the feasibility, surgical safety, and early audiological benefit of the new active transcutaneous bone conduction implant Sentio in pediatric patients. Design: Retrospective case series. Study sample: Seven children (8 ears), aged 3.6 to 9.7 years, underwent implantation of a Sentio system between December 2024 and March 2025 for congenital aural atresia (6 ears) or single-sided deafness due to cochlear nerve aplasia (2 ears). Results: All surgeries were completed successfully using the Sentio Ti Implant. Limited exposure of the dura, sigmoid sinus, and/or mastoid air cells occurred during bone-bed preparation, but there was no laceration, bleeding, cerebrospinal fluid leak, compression, or clinical sequela. No perioperative or postoperative adverse events occurred through initial fitting. Bone conduction thresholds remained stable postoperatively, confirming preservation of cochlear reserve. Mean Sentio-aided free-field thresholds were 22.5, 20.0, 18.6, and 18.6 dB HL at 0.5, 1, 2, and 4 kHz, respectively. Word recognition scores at initial fitting averaged 96.3% in all patients (range: 85-100%) at a conversational level of 65 dB SPL. The relatively flat transducer and flexible band fixation facilitated safe implantation in young children with thin cranial bone. Conclusion: Sentio Ti implantation was technically feasible in this selected cohort, with no clinical adverse events through initial fitting and favorable early aided outcomes. Larger prospective studies with standardized testing and longer follow-up are required to assess long-term safety, skull growth, implant stability, MRI-related limitations, and sustained benefit.

  • A Prospective, Multicenter Clinical Investigation on the Safety and Performance of a New Active Transcutaneous Bone-anchored Implant System

    by Myrthe K.S. Hol, Tjerk W. Aukema, Sander W.J. Ubbink, Dennis Lindholm, Marcus Holmberg, Susan Arndt, Stefanie Wolf, Peter Monksfield, Mihalache Marwa, Thomas Lenarz, et al.

    Was not provided for this article.

  • Twelve-Month Outcomes After Hearing Rehabilitation With an Active Middle Ear Implant and Latest Generation Vibroplasty Couplers in Adults And Children: A Prospective Multicenter Study

    by Kristen Rak, Stefan K. Plontke, Thomas Lenarz, Daniela Hollfelder, Piotr H. Skarzynski, Georg M. Sprinzl, Marcus Neudert, John-Martin Hempel, Wafaa Shehata-Dieler, Rudolf Hagen, et al.

    Objective: To evaluate the audiological efficacy, patient-reported outcomes, and safety of an active middle ear implant (AMEI) in children and adults with distinct coupling options. Study design: Prospective, longitudinal, multicenter, noninterventional observational study with repeated within-subject measures and a 12-month follow-up. Setting: Nine tertiary referral centers in Germany, Austria, and Poland. Patients: Adults and children with sensorineural, conductive, or mixed hearing loss. Adults were grouped by coupling method: incus long process (LP), incus short process (SP), round window (RW), or stapes head (SH); multiple couplers were used in children. Intervention: AMEI with coupler. Main outcome measures: The primary outcome was the difference in speech recognition thresholds for 50% speech recognition (SRT50) in quiet between unaided preoperative and aided 12-month postactivation. Secondary outcomes included SRT50 in noise, sound-field thresholds, patient-reported outcomes, air- and bone-conduction thresholds, and adverse events. Results: Audiological outcomes were evaluated in 67 patients. SRT50 in quiet significantly improved across all subgroups, with large effect sizes (Cohen d z >0.8): 17.9±9.3 dB (LP), 18.3±8.4 dB (SP), 25.3±6.3 dB (RW), 23.1±17.6 dB (SH), and 21.6±9.4 dB in children. SRT50 in noise improved by 4.3 to 9.2 dB, and functional gains ranged from 18.3 to 39.2 dB. Patients reported positive impacts on quality of life and perceived quality of hearing. Two device explantations and 2 revision surgeries occurred. Exploratory analyses showed no statistically detectable differences between coupling approaches. Conclusion: AMEI use was associated with significant audiological and patient‑reported improvements in adults and children. Within the limitations of this observational study, including limited power and baseline heterogeneity, no statistically detectable differences in outcomes were observed between coupling approaches. Coupler selection should therefore remain guided by anatomic and clinical considerations.

  • Open Access

    The Bonebridge BCI 602 Safety and Performance 1 Year Post-Implantation in Adults and Children: A Multicentric Post-Market Study

    by Stefan K. Plontke, Thomas Lenarz, Joseph Toner, Thomas Keintzel, Georg Sprinzl, Wolf-Dieter Baumgartner, Assen Koitschev, Joachim Schmutzhard, Gerrit Götze, Torsten Rahne, et al.

    Objective: To confirm the long-term safety and performance of the Bonebridge BCI 602 in patients suffering from conductive or mixed hearing loss (CMHL) or single-sided deafness (SSD) over a 12-month period post-implantation. Study design: Multicentric, multinational, ambidirectional, observational Post-Market Clinical Follow-Up (PMCF) study. Setting: Eight tertiary referral hospitals. Participants: Fifty-two participants in 3 categories: adults CMHL (N=24), children CMHL (N=17), and SSD (N=11; 9 adults and 2 children). Intervention: Participants were implanted with the Bonebridge BCI 602 device. Main outcome measure(s): Outcome measures focused on sound field thresholds (SF), word recognition scores (WRS), speech reception thresholds (SRT) in both quiet and noise, adverse events, and subjective satisfaction (SSQ and AQoL questionnaires) at initial activation and at 3-month and 12-month post-implantation. Results: Safety was established by stable bone conduction (BC) thresholds and a low adverse event rate with no unanticipated events. Safety was underlined by clinically relevant improvements in the health-related assessment of Quality of Life (AQoL) questionnaire of mean+0.1 (adults and children CMHL) and +0.07 (SSD). Hearing significantly improved in sound field thresholds with mean functional gains of 24.05±8.68 dB (adults CMHL), 21.34±25.43 dB (children CMHL), and 32.89±25.87 dB (SSD). Mean word recognition scores improved by 65.83±28.62 percent points (PP) for adult CMHL and 65.77±27.53 PP for children CMHL and speech reception thresholds (SRT) in quiet by 15.4±9.34 dB and 19.96±14.66 dB, respectively. SRT in noise improved by −5.57±4.23 dB (adults; S 0° N 0° ), −5.12±5.08 dB (children, S 0° N 0° ), and −3.05±3.06 dB (SSD, S SSD N NH ). Subjective hearing ability tested with the Speech, Spatial, and Qualities (SSQ) of Hearing questionnaire improved and was clinically relevant for the adult (+2.23) and children (+1.51) CMHL groups. Conclusions: The Bonebridge BCI 602 demonstrates significant enhancements in hearing and speech understanding 12 months postoperatively, showing high user satisfaction and safety.


  • Open Access

    A Prospective, Multicenter Clinical Investigation on the Safety and Performance of a New Active Transcutaneous Bone-Anchored Implant System

    by Myrthe Karianne Sophie Hol, Tjerk Winus Aukema, Sander Wilhelmus Johannes Ubbink, Dennis Lindholm, Marcus Holmberg, Susan Arndt, Stefanie Wolf, Peter Monksfield, Mihalache Marwa, Thomas Lenarz, et al.

    Objective: To evaluate safety and performance of a new active transcutaneous system, 3 and 6 months postoperatively. Study design: An open, prospective, multicenter clinical investigation with 24-month follow-up. Setting: Six European tertiary referral centers from the Netherlands, Germany, and United Kingdom. Patients: Fifty-one adult patients with conductive hearing loss, mixed hearing loss, or single-sided deafness requiring surgical intervention for bone conduction hearing. Intervention: Implantation and fitting of an active transcutaneous device, the Sentio System. Main outcome measure: Performance outcomes included variables related to surgery (eg, surgery time and postoperative wound healing), audiology (eg, sound field thresholds, speech recognition in quiet and noise), and patient-reported outcomes (eg, quality of life, intervention benefit, and patient satisfaction). Moreover, safety was assessed by continuous reporting of adverse events and serious adverse events. Results: Smooth implant installation with no or limited preoperative imaging, and without major events in the postoperative phase was demonstrated. Audiological assessments showed significant improvements in sound field thresholds, with a mean functional gain of 32.8 dB (PTA4) and a mean effective gain of 9.0 dB. Mean aided speech recognition in quiet was 97.9%, and the improvement in speech-noise-ratio compared with a sound processor on softband was −2.98 dB. The patients reported a high perceived quality of life, with 96.1% reporting improvements post-intervention. Safety was confirmed by a limited amount and mild nature of adverse events. Discussion: The Sentio system provides a safe and effective treatment option, showing significant improvements in hearing outcomes, patient benefits, and quality of life for patients.


  • Open Access

    Precise bonebridge implantation in challenging cases: a novel approach using virtual planning and electromagnetic navigation

    by Nils Kristian Prenzler, Susan Busch, Niels Rudnik, Thomas Lenarz, Daniel Schurzig

    Background: The second generation of the Bonebridge (BB) bone conduction implant was shown to be a viable option even for younger children with conductive or mixed hearing loss. However, preoperative imaging often shows only small areas where the FMT (4.5 mm) or screws (4.0 mm) can be fully and safely inserted without the need to use lifts. Navigation systems allow precise placement of the device and prevent potential complications such as dural or vascular injuries. The latest version of the preoperative planning software Otoplan® allows to assess bone thickness and perform virtual implantation. Materials & methods: Six children between 3 and 12 years of age underwent BB implantation using Otoplan® with export of the planned BB position to a navigation system. Prior to an intraoperative cone beam CT (CBCT), 3 marker screws were placed in the temporal bone. Images were loaded into Otoplan® to virtually define the optimal BB position and export the corresponding model. CBCT scan and model were then loaded into an electromagnetic navigation system. The screws were used to accurately register the system, and the planned BB placement was projected onto the patient. BB implantation was performed accordingly and finally the marker screws were removed. Possible complications were monitored and the audiological success was measured using an age-appropriate speech test. Results: Bone thickness at the screw location was over 4.0 mm in every case, documenting the accuracy of the procedure. No medical complications occurred intraoperatively, during the immediate hospital stay, or up to and including the initial fitting 4–6 weeks after implantation. Speech test results were greater than or equal to 90% in all measurable patients. Conclusion: Virtual implantation with Otoplan® can be loaded into a navigation system to mark the safe position of the screws on the temporal bone. Projecting the planned position onto the patient using navigation is a practical tool that can make implantation more reliable and safer for patients.


  • Open Access

    Alcohol Use Disorder Treatment Availability at Mental Health Treatment Facilities

    by Susan H. Busch, David A. Fiellin, Kaede Iida, Kim Gannon, Melissa B. Weimer, Jason Hockenberry

    This cross-sectional study assesses whether specialty mental health facilities offer treatment for alcohol use disorder to patients with co-occurring mental health disorders and alcohol use disorder.


  • Characteristics of Adults Treated at Mental Health Treatment Centers in the US, 2022

    by Susan H. Busch, Jason Hockenberry, Helen Newton

    This cross-sectional study examines demographic characteristics of adults treated at outpatient mental health treatment centers using data from the 2022 US National Survey of Drug Use and Health.


  • Patients’ Reasons for Using Out-of-Network Mental and General Medical Health Providers

    by Susan H. Busch, Kelly Kyanko

    Objective: The authors sought to assess why patients use out-of-network health care providers and whether patients’ reasons differ for mental and general medical health providers. Methods: In a national Internet survey of commercial plan enrollees (N=713) who used an out-of-network provider, participants indicated whether 12 reasons were “important” (vs. “not applicable” or “not important”) in their decision to see an out-of-network provider. Results: Reasons for using out-of-network care were multifactorial. Six reasons were similarly important, including the three most-cited reasons: convenient location (66% vs. 69% for mental vs. general medical health, respectively), higher quality (65% vs. 69%), and affordability (70% vs. 71%). Reasons more commonly cited for using out-of-network mental health care were that in-network providers were not taking new patients (34% vs. 24%), confidentiality (33% vs. 19%), cultural competence (33% vs. 23%), and inaccurate in-network provider directories (30% vs. 22%). Conclusions: The most common reasons for using out-of-network care were cited with similar frequency for both mental health and general medical health providers.